search
Back to results

Chest Physiotherapy and Lung Function in Primary Ciliary Dyskinesia

Primary Purpose

Primary Ciliary Dyskinesia

Status
Unknown status
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
Chest physiotherapy
Sponsored by
Universitaire Ziekenhuizen KU Leuven
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Primary Ciliary Dyskinesia focused on measuring lung function tests, chest physiotherapy

Eligibility Criteria

6 Years - 50 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Primary ciliary dyskinesia
  • able to perform spirometry and MBW (>6 years)

Exclusion Criteria:

  • acute exacerbation

Sites / Locations

  • University Hospital Gasthuisberg LeuvenRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

chest physiotherapy

Arm Description

session of 20 minutes chest physiotherapy with physiotherapist, use of airway clearance techniques, PEP (positive expiratory pressure) device

Outcomes

Primary Outcome Measures

Difference in FEV1 before and after treatment
Lung function will be performed before a session of chest physiotherapy, and repeated 30 minutes after a chest physiotherapy session of 20 minutes with airway clearance techniques and use of PEP mask

Secondary Outcome Measures

Difference in LCI before and after chest physiotherapy
Multiple Breath Washout (MBW) will be performed before and 30 min after a session of chest physiotherapy. The difference in LCI (lung clearance index) will be used as secondary outcome.

Full Information

First Posted
August 22, 2013
Last Updated
September 29, 2021
Sponsor
Universitaire Ziekenhuizen KU Leuven
search

1. Study Identification

Unique Protocol Identification Number
NCT01929356
Brief Title
Chest Physiotherapy and Lung Function in Primary Ciliary Dyskinesia
Official Title
The Influence of Chest Physiotherapy on Lung Function Parameters in Primary Ciliary Dyskinesia
Study Type
Interventional

2. Study Status

Record Verification Date
September 2021
Overall Recruitment Status
Unknown status
Study Start Date
June 30, 2020 (Actual)
Primary Completion Date
November 2021 (Anticipated)
Study Completion Date
November 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Universitaire Ziekenhuizen KU Leuven

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Primary ciliary dyskinesia (PCD) is a rare disease, caused by impairment of the motile cilia. Patients present with chronic upper and lower respiratory tract infections. The therapy is mainly supportive and based on that of cystic fibrosis. Chest physiotherapy is one of the cornerstones of the therapy, however the influence of chest physiotherapy on lung function (short term and long term) is not clear. For interpretation of longitudinal lung function data it is important to examine the short time effect of chest physiotherapy. We hypothesize that a session of chest physiotherapy improves lung function and that thus lung function tests must be performed in a standardized way.
Detailed Description
Primary ciliary dyskinesia (PCD) is a rare disease, caused by congenital dysfunction of the motile cilia, located in the upper and lower respiratory tract, in the reproductive system and in the embryonal node. Ineffective ciliary beating results in disturbed mucociliary clearance, which is an important defense mechanism in the respiratory tract. It causes recurrent and chronic upper and lower respiratory tract infections, leading to reversible (mucus plugging) and irreversible lung damage (bronchiectasis, atelectasis, mucus plugging). Just like cystic fibrosis, it is characterized by obstructive lung disease, measured by spirometry. Using Multiple Breath Washout measurements, it has been shown that peripheral airways disease is present in PCD. Probably, MBW parameters are already abnormal before forced expiratory volume in one second is abnormal. The therapy for patients with PCD is mainly supportive: regular oral or intravenous antibiotics to treat airway infections and chest physiotherapy to actively increase mucociliary clearance. Chest physiotherapy has the objective to clear mucus from the lungs. Guidelines support the treatment of patients with PCD with chest physiotherapy. It is known that in patients with PCD, exercise has a more bronchodilating effect than the administration of salbutamol. However, no objective data describe the acute effect of chest physiotherapy on spirometry and MBW parameters. Moreover, short term effects of intervention on spirometry and MBW parameters can influence the interpretation of long-term evolution of these parameters. In cystic fibrosis, one study has assessed the short-term influence of chest physiotherapy on lung function, measured by spirometry and MBW before and after chest physiotherapy. The authors found no significant influence of chest physiotherapy on spirometry parameters, nor on MBW parameters. Therefore, longitudinal interpretation can be performed irrespective of the timing of the lung function measurements. However, cystic fibrosis and PCD have a different pathophysiological mechanism with a more 'mechanical' disturbance of the mucociliary clearance in PCD, compared to a more 'viscous' disturbance of mucociliary clearance in CF. Therefore, the results in CF are not applicable to PCD. Even more, we hypothesize that chest physiotherapy will have a significant effect on lung function parameters (spirometry and MBW) in patients with PCD due to its external mechanical effect on mucus clearance.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Ciliary Dyskinesia
Keywords
lung function tests, chest physiotherapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
29 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
chest physiotherapy
Arm Type
Experimental
Arm Description
session of 20 minutes chest physiotherapy with physiotherapist, use of airway clearance techniques, PEP (positive expiratory pressure) device
Intervention Type
Procedure
Intervention Name(s)
Chest physiotherapy
Intervention Description
20 minutes of chest physiotherapy by physiotherapist
Primary Outcome Measure Information:
Title
Difference in FEV1 before and after treatment
Description
Lung function will be performed before a session of chest physiotherapy, and repeated 30 minutes after a chest physiotherapy session of 20 minutes with airway clearance techniques and use of PEP mask
Time Frame
30 minutes
Secondary Outcome Measure Information:
Title
Difference in LCI before and after chest physiotherapy
Description
Multiple Breath Washout (MBW) will be performed before and 30 min after a session of chest physiotherapy. The difference in LCI (lung clearance index) will be used as secondary outcome.
Time Frame
30 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Primary ciliary dyskinesia able to perform spirometry and MBW (>6 years) Exclusion Criteria: acute exacerbation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mieke Boon, MD
Phone
+3216342589
Email
mieke.boon@uzleuven.be
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mieke Boon, MD
Organizational Affiliation
research fellow
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Gasthuisberg Leuven
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mieke Boon, MD
Phone
+3216342589
Email
mieke.boon@uzleuven.be
First Name & Middle Initial & Last Name & Degree
Christiane De Boeck, MD, Phd
Phone
+3216343820
Email
christiane.deboeck@uzleuven.Be
First Name & Middle Initial & Last Name & Degree
Mieke Boon, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Chest Physiotherapy and Lung Function in Primary Ciliary Dyskinesia

We'll reach out to this number within 24 hrs